An influence of the parathyroid hormone on metabolic processes in severe glucocorticoid osteoporosis

Authors

  • Sergey Zolotukhin
  • Hasan Aussie
  • Mykola Shpachenko
  • Yury Kryuk
  • Dmitry Pyrko

DOI:

https://doi.org/10.15674/0030-59872009145-48

Keywords:

glucocorticoid osteoporosis, Teriparatide

Abstract

The article contains data on the modelling of experimental glucocorticoid osteoporosis. Severe, moderate and mild osteoporoses were diagnosed by X-ray criteria. In order to assess degrees of metabolic disturbances in osteoporosis, 11 biochemical indices were reduced to a single scale of values with reference to the control level and studied. Teriparatide, injected subcutaneously at a dose of 5 mcg/kg, was used for the treatment. It was revealed, that Teriparatide inhibited the pathological process, which had already developed, and produced a restorative effect in osteoporosis. This kind of its action, synchronous with withdrawal of Prednisolon, reduced metabolic processes, eventually increasing the life-span of the rats with osteoporosis. Taking into account a positive influence of Teriparatide on metabolism, an effect of the stimulation of osteoblast activity in the drug action mechanism may be assumed. Hence, Teriparatide in glucocorticoid osteoporosis had an expressed therapeutic effect manifested by a reduction of metabolic disturbances and an increase in the life-span of the rats.

References

  1. Беневоленская Л.И. Проблема остеопороза в современной медицине / Л.И. Беневоленская // Вестник РАМН. — 2003. — № 7. — С. 15–18.
  2. Буфистова А.В. Прогнозирование тяжести течения глюкокортикоидного остеопороза(экспериментальное исследование) / А.В. Буфистова, С.Е. Золотухин, В.П. Коробов [и др.] // Загальна патологія та патологічна фізіологія. — 2006. — Т. 1, № 2. — Додаток А. — С. 64–74.
  3. Ермоленко В.Н. Фосфорно-кальциевый обмен и почки // Нефрология: Руководство для врачей / [под ред. И.Е. Тареевой]. — М.: Медицина, 2000. — С. 62–75.
  4. Кластер У. Нарушения минерального обмена и костного метаболизма: терапевтический справочник Вашингтонского университета / [под ред. М. Вудли и А. Уэлан]. — М.: Практика, 1995. — С. 502–601.
  5. Климовицкий В.Г. Влияние гормонов щитовидной и паращитовидной желез на механизмы резорбции и формирования костной ткани при глюкокортикоидном остеопорозе (экспериментальное исследование) / В.Г. Климовицкий, С.Е. Золотухин, А.В. Буфистова [и др.] // Український морфологічний альманах. — 2005. — Т. 3, № 1. — С. 30–34.
  6. Тесняк О.М. Медикаментозные методы лечения остеопороза / О.М. Тесняк // Ревматология. — 2005. — Т. 7, № 2. — С. 29–36.
  7. Benson C.T. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin / C.T. Benson, J.R. Voelker // J. Clinical Pharmacology Therapy. — 2003. — V. 73. — P. 87–94.
  8. Body J.J. A randomized double-blind triol compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal Women with osteoporosis / J.J. Body, G.A. Gaich, W.H. Scheele [et al.] // J. Clinical Endocrinology and Metabolism. — 2002. — V. 87. — P. 4528–4535.
  9. Juppner H. A G-proteinlinked receptor for parathyroid hormone and parathyroidrelated peptide / H. Juppner, A.B. Abon-Samra,M. Freeman [et al.] // Science. — 1991. — V. 254. — P. 1024–1026.
  10. Mosekilde Li. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in sexually nature, ovariectomized rat model / Li Mosekilde, C.C. Danielsen, C.H. Sogaard [et al.] // Bone. — 1995. — V. 16. — P. 223–230.
  11. Sambrook Ph. Osteoporosis / Ph. Sambrook, C. Cooper // Lancet. — 2006. — T. 367. — P. 2010–2018.

Downloads

How to Cite

Zolotukhin, S., Aussie, H., Shpachenko, M., Kryuk, Y., & Pyrko, D. (2009). An influence of the parathyroid hormone on metabolic processes in severe glucocorticoid osteoporosis. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (1), 45–48. https://doi.org/10.15674/0030-59872009145-48

Issue

No. 1 (2009)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2014 Sergey Zolotukhin, Hasan Aussie, Mykola Shpachenko, Yury Kryuk, Dmitry Pyrko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).